Champions Oncology Inc (CSBR)

[Milburn D]

Champions Oncology Reports Successful Outcome From Technology Collaboration

HACKENSACK, N.J., Feb 11, 2013 (GLOBE NEWSWIRE via COMTEX) -- Champions
(OTC:CSBR) announced the successful completion of a TumorGraft technology
collaboration with a subsidiary of Teva Pharmaceutical Industries, Ltd.
("Teva"). The collaboration was originally initiated in March of 2011 and
included extensive evaluation of the efficacy and differentiation of CEP-32496,
a dual B-Raf and EGFR inhibitor, one of Teva's proprietary late stage
pre-clinical chemical compounds using 24 Champions TumorGraft(TM) models of
B-Raf mutated human melanoma and colorectal cancer against standard of care
drugs and targeted therapeutic agents. The results demonstrated that the
compound met the predetermined success criteria. As part of the original
agreement, Teva is obligated to pay Champions either milestone and royalty
payments upon future development of the compound, or a one-time cash payment
upon successful conclusion of the TumorGraft analysis. As a result of the
successful outcome, Teva has exercised its right to make the one-time payment in
the amount of $880,000 in lieu of the future payments.

Joel Ackerman, the CEO of Champions Oncology, commented, "We are excited about
the positive outcome that our TumorGraft platform has delivered. This study
validates the value that our TumorGrafts deliver to our clients and the
importance they play in the process of oncology drug development."

About Champions Oncology, Inc.

Champions Oncology, Inc. is engaged in the development of advanced technology
solutions and services to personalize the development and use of oncology drugs.
The Company's TumorGraft Technology Platform is a novel approach to
personalizing cancer care based upon the implantation of primary human tumors in
immune deficient mice followed by propagation of the TumorGrafts in a manner
that preserves the biological characteristics in order to determine the efficacy
of a treatment regimen. The Company uses this technology to offer solutions for
Personalized Oncology Solutions, which guides the development of personalized
treatment plans, and Translational Oncology Solutions, which assists
pharmaceutical and biotechnology companies seeking personalized approaches to
drug development to lower the cost and increase the speed of drug development.

For more information, visit www.championsoncology.com.

This press release may contain "forward-looking statements" (within the meaning
of the Private Securities Litigation Act of 1995) that inherently involve risk
and uncertainties. Champions Oncology generally uses words such as "believe,"
"may," "could," "will," "intend," "expect," "anticipate," "plan," and similar
expressions to identify forward-looking statements. One should not place undue
reliance on these forward-looking statements. The Company's actual results could
differ materially from those anticipated in the forward-looking statements for
many unforeseen factors. See Champions Oncology's Form 10-K for the fiscal year
ended April 30, 2012 for a discussion of such risks, uncertainties and other
factors. Although the Company believes the expectations reflected in the
forward-looking statements are reasonable, they relate only to events as of the
date on which the statements are made, and Champions Oncology's future results,
levels of activity, performance or achievements may not meet these expectations.
The Company does not intend to update any of the forward-looking statements
after the date of this press release to conform these statements to actual
results or to changes in Champions Oncology's expectations, except as required
by law.



CONTACT: Gary Gemignani

Champions Oncology, Inc.

201-808-8408

[e-mail]



Lauren Kwiecinski

The Trout Group LLC

646-378-2934

[e-mail]

http://www.globenewswire.com/newsroom/ti?nf=MTMjMTAwMjEyMzEjMjM4NzM=




(C) Copyright 2013 GlobeNewswire, Inc. All rights reserved.

-0-




KEYWORD: HACKENSACK, N.J.

INDUSTRY KEYWORD: Healthcare & Medical Services

SUBJECT CODE: Product / Services Announcement

MEDICAL

BIOTECHNOLOGY